International Journal of Surgical Oncology / 2022 / Article / Tab 4 / Research Article
High CD44 Immunoexpression Correlates with Poor Overall Survival: Assessing the Role of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma Patients from the High-Risk Population of Pakistan Table 4 Correlations of antibody expression and patient characteristics.
Clinicopathologic parameters Total cases CD133 CD44 L1CAM SOX2 −ve +ve Low High −ve +ve −ve +ve Age <40 years 18 11 7 0.077 9 9 0.090 12 6 0.465 6 12 0.722 ≥40 years 82 66 16 58 24 47 35 31 51 Gender Male 57 41 16 0.165 38 19 0.935 30 27 0.136 19 38 0.382 Female 43 36 7 29 14 29 14 18 25 Habits Yes 79 56 23 0.003 54 25 0.576 46 33 0.761 30 49 0.695 No 21 21 0 13 8 13 8 7 14 Betel quid/areca nut Yes 61 42 19 0.015 43 18 0.353 37 24 0.674 22 39 0.809 No 39 35 4 24 15 22 17 15 24 Smoking/tobacco use Yes 35 25 10 0.331 23 12 0.841 19 16 0.482 9 26 0.086 No 65 52 13 44 21 40 25 28 37 Chalia/gutka/naswar Yes 31 20 11 0.047 20 11 0.723 16 15 0.314 15 16 0.114 No 69 57 12 47 22 43 26 22 47 Habit pattern Single 37 27 10 0.929 25 12 0.848 22 15 0.934 16 21 0.613 Multiple 42 29 13 0.998 29 13 0.663 24 18 0.855 14 28 0.460 Non-users 21 21 0 0.998 13 8 0.571 13 8 0.718 7 14 1 Primary tumour site Cheek 63 48 15 0.802 41 22 0.594 36 27 0.622 22 41 0.574 Tongue 37 29 8 26 11 23 14 15 22 Palate Yes 8 6 2 1 6 2 1 5 3 1 3 5 1 No 92 71 21 61 31 54 38 34 58 Mandible Yes 26 22 4 0.283 15 11 0.241 14 12 0.535 10 16 0.858 No 74 55 19 52 22 45 29 27 47 Floor of the mouth Yes 7 3 4 0.047 2 5 0.038 2 5 0.119 3 4 0.708 No 93 74 19 65 28 57 36 34 59 Tonsils Yes 2 0 2 0.051 0 2 0.107 0 2 0.166 1 1 1 No 98 77 21 67 31 59 39 36 62 Skin Yes 3 3 0 1 2 1 1 1 2 0.566 0 3 0.294 No 97 74 23 65 32 58 39 37 60 Differentiation Well differentiated 37 25 12 0.313 26 11 0.790 21 16 0.785 18 19 0.131 Moderately differentiated 59 48 11 0.127 38 21 0.554 35 24 0.804 17 42 0.052 Poorly differentiated 4 4 0 0.999 3 1 0.844 3 1 0.491 2 2 0.959 Primary margins Clear 62 48 14 0.938 42 20 0.964 36 26 0.476 23 39 0.783 Near 27 21 6 0.970 18 9 0.921 18 9 0.446 9 18 0.734 Involved 11 8 3 0.735 7 4 0.790 5 6 0.440 5 6 0.600 T classification T1 21 17 4 0.461 18 3 0.058 14 7 0.636 8 13 0.849 T2 47 33 14 0.358 32 15 0.138 27 20 0.474 16 31 0.747 T3 15 12 3 0.943 6 9 0.007 7 8 0.234 7 8 0.608 T4 17 15 2 0.544 11 6 0.140 11 6 0.899 6 11 0.859 N classification N0 77 60 17 0.856 54 23 0.413 46 31 0.921 27 50 0.732 N1 13 10 3 0.936 8 5 0.538 7 6 0.690 6 7 0.445 N2 10 7 3 0.577 5 5 0.209 6 4 0.987 4 6 0.759 AJCC clinical stage I 19 15 4 0.692 16 3 0.157 13 6 0.569 8 11 0.768 II 32 23 9 0.576 23 9 0.321 17 15 0.286 10 22 0.434 III 23 17 6 0.703 12 11 0.036 12 11 0.288 10 13 0.929 IV 26 22 4 0.624 16 10 0.107 17 9 0.831 9 17 0.609 Radiotherapy Yes 65 49 16 0.601 41 24 0.256 41 24 0.259 22 43 0.373 No 25 28 7 26 9 18 11 15 20 CD133 Positive 23 — — — 15 8 0.836 10 13 0.850 9 14 0.809 Negative 77 — — 52 25 49 28 28 49 CD44 High 33 25 8 0.836 — — — 20 13 0.819 14 19 0.43 Low 67 52 15 — — 39 28 23 44 L1CAM Positive 41 28 13 0.085 28 13 0.819 — — — 17 24 0.441 Negative 59 49 10 39 20 — — 20 39 SOX2 Positive 63 49 14 0.809 44 19 0.43 39 24 0.441 — — — Negative 37 28 9 23 14 20 17 — —